Wegovy is the brand name of semaglutide, a GLP-1 receptor agonist used with reduced-calorie diet and increased physical activity for chronic weight management, cardiovascular risk reduction in adults with established cardiovascular disease and obesity/overweight, and treatment of noncirrhotic MASH with moderate-to-advanced fibrosis under accelerated approval. U.S. initial approval in this label is 2017.
The White House reports a 3.1% drop in prescription drug prices over the past year, the steepest decline since 1963, attributing it to President Trump's Most Favored Nation policies and TrumpRx discounts. Drugmakers like Pfizer have agreed to significant price cuts on several medications.
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
Adding bacteriostatic water to a 3mg semaglutide vial changes its concentration; the correct amount depends on the pharmacy's specification. FDA-approved semaglutide pens should not be reconstituted. The FDA has received reports of hospitalizations linked to compounded semaglutide dosing errors.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
Pharmaceutical manufacturers are shifting to greener production methods for GLP-1 peptide weight-loss drugs like Ozempic and Wegovy, reducing reagent waste and moving away from restricted solvents. The traditional process uses up to 13,000 kg of reagents per kg of peptide. Expert Fernando Albericio also calls for ethical use of these medications, often dubbed 'Hollywood drugs.'
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07090343 |
Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement |
NOT_YET_RECRUITING | PHASE3 |
| NCT07036172 |
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients |
RECRUITING | PHASE3 |
| NCT06830343 |
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity |
RECRUITING | PHASE1 |
